Without functional non-conjugation enzymes, reactive intermediates accumulate and overwhelm the conjugation machinery, creating a bottleneck that drives oxidative stress and tissue damage
The STEP-1 trial framework (N=1,961 in semaglutide research) demonstrates how rigorously a drug-drug interaction profile should be established before widespread clinical use [10]
High production costs of advanced formulations affect affordability for price-sensitive consumers
Mechanistic investigations revealed that the therapeutic effects originate from activation of the Nrf2-ARE signaling pathway, which simultaneously suppresses inflammatory cytokine expression and upregulates antioxidant enzymes, including HO-1 and NQO-1
Moreover, recent frameworks extend these strategies to inflammatory and pulmonary diseases, where similar trigger-based principles guide the rational selection of linkers and cross-linking chemistries for in vitroin vivo correlation (Kalkal et al., 2025